dee757c0691e9c6fda1d5c86aedafa5461fe6dc6a3feed254eb781f7491cddda
Licensed Research: FDA-Approved Medicine Filing Methodology
Publicly online since 2010 · U.S. patent applications since 2012 · inventions offered since 2014. The work of Christopher Gabriel Brown, independently documented.
This item is delivered by Christopher Gabriel Brown by email within 24 hours of your order. You'll receive the deliverable at the email on your order. USA delivery only. Founder Access Pass credit (code FAP99CREDIT) applies at checkout automatically.
The True-to-Life Method of Filing an FDA-Approved Medicine
The real regulatory road a new prescription medicine travels in the United States — every actual step, form, phase, timeline, and cost, from the lab bench to the pharmacy shelf. There are no shortcuts in the core path, only a few optional lanes that speed the review, not the science.
|
Product |
|
|
Subject |
The real US FDA drug-approval process (educational) |
|
Typical timeline |
10–15 years · ~$0.7B–$2.6B · ~1 in 10 approved from first human dose |
|
Regulator |
FDA — CDER (drugs) / CBER (biologics) |
|
Inventor / Author |
Christopher Gabriel Brown, Lawrenceville, GA, USA |
|
Price |
$0.00 — Licensed Research |
01 How to read this set
This is the master map. Read it first, then the companions that place specific licensed discoveries on this exact road:
- This guide — the full approval road, start to finish.
- Where My Three Disease Discoveries Sit on the FDA Road — the overview of all three at once.
- Per-disease companions: Diabetes, Alzheimer’s, and Parkinson’s on the Real FDA Road — each ending with the one lawful way to make it as a dietary supplement.
- The licensed packages themselves: the Diabetes, Alzheimer’s, and Parkinson’s Mechanism Analyses.
All in the Licensed Research category: cri-one.com/store/licensed-research.html.
02 The seven stages, with the real forms
|
Stage |
What happens |
|
0 · Preclinical |
Lab + animal testing under Good Laboratory Practice (GLP, 21 CFR 58); build the manufacturing package (CMC). Goal: reasonably safe to try in a few humans. |
|
1 · IND |
Investigational New Drug application — Form FDA 1571 (+ 1572 per investigator, 3674 for ClinicalTrials.gov). Then a mandatory 30-day wait; IRB approval; informed consent; GCP. |
|
2 · Trials |
Phase 1 (20–80, safety) → Phase 2 (≤300, efficacy) → Phase 3 (≤3,000, confirm). ~1 in 10 of those entering trials is ever approved. |
|
3 · NDA/BLA |
The marketing application — Form FDA 356h + a PDUFA user fee (a fiscal-2025 standard application with clinical data runs ~$4M). |
|
4 · Review |
60-day filing decision; ~10-month standard / ~6-month priority review; possible advisory committee; pre-approval cGMP inspection (21 CFR 210/211). |
|
5 · Decision |
Approval Letter — or a Complete Response Letter (CRL) listing deficiencies to fix and resubmit. |
|
6 · Post-market |
Phase 4 commitments; adverse events to FAERS via MedWatch; REMS for high-risk drugs; supplements for any change. |
03 The three filing pathways
- 505(b)(1) — a full NDA backed entirely by your own new studies (brand-new molecules).
- 505(b)(2) — an NDA relying partly on data you did not generate (reformulations, new combinations, new uses).
- 505(j) — an ANDA (Abbreviated NDA) for a generic: no new efficacy trials, instead prove bioequivalence to the reference product.
04 The optional fast lanes (and OTC)
- Fast Track — serious unmet need; allows rolling submission.
- Breakthrough Therapy — intensive FDA guidance on strong early data.
- Accelerated Approval — approval on a surrogate endpoint, with confirmatory trials required after.
- Priority Review — shortens the review goal from ~10 to ~6 months.
OTC: most over-the-counter drugs need no individual approval if they match an FDA OTC Monograph (updated by administrative order since the 2020 CARES Act). A prescription-to-OTC switch does require an application.
05 The path in one line
Discovery → Preclinical (GLP) → IND (Form 1571 + 30-day wait) → Phase 1 → Phase 2 → Phase 3 (IRB + informed consent, GCP) → NDA/BLA filing (Form 356h + PDUFA fee) → 60-day filing decision → ~6–10 month review + cGMP inspection [± advisory committee] → Approval Letter or Complete Response Letter → Post-market Phase 4 / FAERS / REMS.
Inquiries
Christopher Gabriel Brown — Inventor & Licensor
crioneaka@outlook.com ·
1341 Wellington Cove, Lawrenceville, GA 30043-5255, USA
Related work by the same author: Chemical Cooker Laboratory — cri-one.com/store/chemical-cooker-laboratory.html
Educational, plain-language summary of the publicly documented US FDA drug-approval process. Not legal, medical, or regulatory advice; not affiliated with or endorsed by the FDA. Rules, fees, and timelines change — always confirm against current FDA guidance before acting.
© 2026 Christopher Gabriel Brown. All rights reserved. “Cri-One” and “Licensed Research” are product designations of the licensor. Patents retained; not sold.
